First Trust Growth Strength ETF(FTGS.US)

Company Encyclopedia
View More
name
First Trust Growth Strength ETF
FTGS.US
News
View More

Moody’s Analytics’ Mark Zandi says 'no jobs' could be focus of Fed in 2026

Mark Zandi, chief economist at Moody's Analytics, joins 'Squawk on the Street' to discuss the impact of tariffs on the economy, the 2026 market outlook, and more.

MSN·
US
MCO
-0.38%
MSN·
US
MCO
-0.38%

Crypto kiosk operator Coinstar is being sold in a deal that will clear its debt in one sweep

Coinstar, a coin-exchange and crypto kiosk operator owned by Apollo Global Management, is being sold in a deal that will clear its debt. The buyer, Arctic Slope Regional Corporation, will repay over $750 million in principal and interest, ensuring a full bond repayment next month. This transaction, which has not been publicly disclosed before, allows Coinstar to transition to an Alaska-based owner while eliminating its bond debt. Coinstar has expanded into digital assets, allowing customers to buy cryptocurrency through kiosks and a mobile app.

Cryptopolitan·
US
APO
-0.66%
Cryptopolitan·
US
APO
-0.66%

Pharmaceutical Stocks To Follow Now - December 31st

Eli Lilly, Pfizer, and Axsome Therapeutics are highlighted as key pharmaceutical stocks to watch, according to MarketBeat. These companies have shown high trading volumes recently, indicating investor interest. Eli Lilly focuses on diabetes and obesity treatments, Pfizer offers a range of medicines and vaccines, and Axsome develops therapies for CNS disorders. The pharmaceutical sector presents potential high returns but also carries significant risks due to regulatory and clinical challenges. Investors are advised to consider these stocks carefully amid market volatility.

Market Beat·
US
PFE
-0.22%
US
LLY
-0.17%
US
AXSM
+23.14%
Market Beat·
US
PFE
-0.22%
US
LLY
-0.17%
US
AXSM
+23.14%

This Is What Whales Are Betting On AppLovin

Financial giants are bullish on AppLovin (NASDAQ:APP), with 57 unusual trades analyzed. 43% of traders are bullish, while 38% are bearish. The predicted price range is between $340.0 and $1110.0. AppLovin's current price is $693.61, down -0.01%. Analysts maintain Buy ratings, with target prices of $775 and $860. The company generates 80% of its revenue from its DSP, AppDiscovery, and is focused on growth through its ad optimizer, AXON 2. Options trading shows significant activity, indicating market interest.

benzinga_article·
US
APP
-2.36%
benzinga_article·
US
APP
-2.36%

BUZZ-Structure Therapeutics doubles while other obesity drug developers decline

Shares of Structure Therapeutics have more than doubled this year, following a 33% decline in 2024, after reporting positive results for its oral obesity pill. In contrast, shares of Viking Therapeutics and Altimmune are declining, with Viking down 12.2% and Altimmune down 49.9% this year. The weight-loss drug market is expected to generate $150 billion in annual sales over the next decade, with major players like Novo Nordisk and Eli Lilly leading the sector.

Reuters·
US
LLY
-0.17%
US
NVO
-0.36%
US
GPCR
-0.18%
Reuters·
US
LLY
-0.17%
US
NVO
-0.36%
US
GPCR
-0.18%
© 2025 Longbridge｜Disclaimer